Topic
Earnings Analysis
4 articles

PAVmed
PAVmed Q3 earnings analysis: EsoGuard Medicare payments begin
PAVmed's preliminary third-quarter results show $1.2 million of EsoGuard revenue at Lucid Diagnostics, a $1.2 million adjusted loss and $8.9 million of cash.

Lucid
Lucid Q3 earnings analysis: $2.74 loss and a $1.75B PIF loan
Lucid missed Q3 revenue and loss estimates, then added $1.75 billion to a Saudi PIF loan, lifting liquidity to $3.75 billion and funding it into late 2027.

Rheinmetall
Rheinmetall earnings guidance cut: shares fall 16% on Boxer delay
Rheinmetall trimmed its 2026 sales and margin outlook for the second time since August on Boxer and ammunition delays, despite a 36% rise in Q3 sales.
Guide
Analyst Estimates and Consensus Explained: Beats, Misses, Revisions
How analyst estimates are built, how consensus is calculated and what a beat or miss compares. Covers research independence and company disclosure rules.